Addressing and Treating Iron Deficiency to Improve Symptoms and Outcomes in Patients with Heart Failure

Launch Date: December 12, 2023
Expiration Date: December 12, 2024

This activity is jointly provided by Partners for Advancing Clinical Education and Cardiometabolic Health Congress.

This activity is supported by an educational grant from American Regent.

Program Overview:

Iron deficiency (ID) with or without anemia is a common comorbidity in patients with heart failure (HF), and it can have significant impacts on morbidity and mortality. Intravenous (i.v.) iron repletion in HF patients with ID can improve symptoms, quality of life, and outcomes, and this evidence has been reflected accordingly in HF guidelines, in addition to a recent FDA approval. During this activity, experts discuss the latest evidence and considerations about the screening, diagnosis, and treatment of ID in patients with HF.

This activity is part of the Know ID in HF Digital Education Hub.

---

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:

• Discuss the prevalence and clinical burden of iron deficiency in HF patients.
• Summarize current and emerging diagnostic approaches aimed to optimize the early diagnosis of ID in patients with HF.
• List the efficacy and safety of intravenous iron repletion for the treatment of iron deficiency in HF patients, as well as recent approvals.
• Review guideline recommendations for the treatment of iron deficiency in patients with HF.
• Select individualized treatment regimens to manage ID in HF patients, including the administration of intravenous iron, based on the current evidence and guideline recommendations.

---

TARGET AUDIENCE

The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.

---

FACULTY

Javed Butler, MD, MPH, MBA
President, Baylor Scott and White Research Institute
Maxwell A. and Gayle H. Clampitt Endowed Chair
Dallas, TX
Distinguished Professor of Medicine, University of Mississippi,
Jackson, MS

Gurusher Panjrath, MD, FACC, FAHA
Professor of Medicine
Director, Heart Failure and Mechanical Support Program
George Washington University School of Medicine and Health Sciences
Washington D.C.

Ileana L Piña, MD, MPH, FAHA, FACC, FHFSA
Professor of Medicine, Thomas Jefferson University
Quality Chief for the CV Line
Clinical Professor of Medicine, Central Michigan University College of Medicine
Adjunct Professor of Epidemiology and Biostats, Case Western University
Population & Quantitative Health Sciences
Senior Staff Fellow, Medical Officer FDA, CDRH

---

JOINT PROVIDERSHIP STATEMENT

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.

PHARMACY CONTINUING EDUCATION

PACE designates this continuing education activity for 1.0contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-23-320-H01-P. Type of activity: Application

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

---

METHOD OF PARTICIPATION & REQUEST FOR CREDIT

There are no registration fees for this activity. Participation in this self-study activity should be completed in approximately 1.0 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from December 15, 2023 through December 15, 2024.

1. Review the objectives and disclosures
2. Study the educational content
3. Successfully complete activity post-test(s)
4. Complete the activity evaluation

You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. Upon completing, your certificate will be available for print. For additional information about the accreditation of this activity, please visit https://partnersed.com

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

DISCLOSURES

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr. Butler, faculty for this educational activity, has the following relevant financial relationships:
Consultant: Abbott, American Regent, Amgen, Applied Therapeutic, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CVRx, Cytokinetics, Edwards, Element Science, Innolife, Impulse Dynamics, Imbria, Inventiva, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Roche, Sequana, SQ Innovation, and Vifor
Speaker: AstraZeneca, Bayer, Boehringer Ingelheim, Impulse Dynamics, Lexicon, Merck, Novartis, and Vifor

Dr. Panjrath, faculty for this educational activity, has the following relevant financial relationships:
Advisor: CVRx
Speaker: Pfizer

Dr. Piña, faculty for this educational activity, has the following relevant financial relationships:
Advisor: Boehringer Ingelheim

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.